Tianze Yuntai's application for IPO on the Science and Technology Innovation Board has been accepted, and currently no drugs have been approved for listing.

According to the Securities Times app, on June 17th, Shanghai Tianze Yuntai Biomedical Pharmaceutical Co., Ltd. (referred to as Tianze Yuntai) has submitted its IPO application to the Shanghai Stock Exchange Science and Technology Innovation Board. Guotai Junan Securities is its sponsor, and it plans to raise 2.503 billion yuan.